Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT04159844 Recruiting - Healthy Subjects Clinical Trials

Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects

FUSION
Start date: September 3, 2019
Phase: N/A
Study type: Interventional

This study evaluates the stiffness and interface pressures of a new compression system URGOBD001 on healthy subjects, compares with a short stretch bandage and a multi component bandage.

NCT ID: NCT04158102 Completed - Healthy Subjects Clinical Trials

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Start date: November 7, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects

NCT ID: NCT04150224 Completed - Healthy Subjects Clinical Trials

Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

Start date: July 3, 2018
Phase: Phase 1
Study type: Interventional

Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers

NCT ID: NCT04146129 Completed - Healthy Subjects Clinical Trials

A Phase 1 Study of CDX-0159

Start date: October 29, 2019
Phase: Phase 1
Study type: Interventional

This is a study to determine the safety of CDX-0159 in healthy subjects.

NCT ID: NCT04123288 Completed - Healthy Subjects Clinical Trials

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

Start date: December 16, 2019
Phase: Phase 1
Study type: Interventional

This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the pharmacokinetics of 2 different formulations of ACT-709478 in healthy male participants. The participants will be treated in a crossover design with 2 different treatment periods. Pharmacokinetics (PK) is the study of the absorption and breakdown of the study drug in the body. The duration of participation in this study is approximately 8 weeks from screening to the end of study visit. A screening visit is required within 21 to 3 days prior to the start of the study to determine whether the participant qualifies and is willing to enter in this research study. This study requires the participant to have two in-patient stays in the research clinic. Each in-patient stay is planned for 5 days (4 nights). Eleven days after each dose the participant will have an examination. There will be an in-between period (i.e., time between the end of period 1 and study treatment administration in Period 2) of 7 to 14 days. A safety follow-up telephone call for all participants who have received at least one study treatment will take place 30 to 40 days after the end of study examination or study discontinuation.

NCT ID: NCT04099225 Completed - Healthy Subjects Clinical Trials

Multiple Breath Washout (MBW) Using Sulfur Hexafluoride Reference Values and Influence of Anthropometric Parameters

Start date: August 2015
Phase:
Study type: Observational

Multiple breath washout (MBW) using Sulphur hexafluoride (SF6) has the potential to reveal ventilation heterogeneity in obstructive lung disease which is frequent in patients with small airway disease. However, it is missed by commonly used tests with reference data being scarce and mostly restricted to younger collectives. We aimed to evaluate the influence of anthropometric parameters on SF6-MBW reference values in pulmonary healthy adults.

NCT ID: NCT04096157 Completed - Healthy Subjects Clinical Trials

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Start date: September 24, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of isavuconazole following a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) compared to a single dose of isavuconazonium sulfate capsules for oral administration (i.e., oral capsules administered to nonintubated participants)(reference formulation). In addition, this study will evaluate the safety and tolerability of isavuconazole and the general pharmacokinetic (PK) parameters of isavuconazole when administered as a single dose of isavuconazonium sulfate IV solution via NG tube (test formulation) and a single dose of isavuconazonium sulfate capsules for oral administration (i.e., oral capsules administered to nonintubated participants) (reference formulation) under fasting conditions in healthy male and female participants.

NCT ID: NCT04072146 Completed - Healthy Subjects Clinical Trials

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Start date: August 26, 2019
Phase: Phase 1
Study type: Interventional

To assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength compared to varenicline administered orally at its highest oral tablet strength.

NCT ID: NCT04068259 Terminated - Healthy Subjects Clinical Trials

Single Ascending Dose Study of PBI-4547 in Healthy Subjects

Start date: September 5, 2019
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of PBI-4547 in healthy adult participants.

NCT ID: NCT04028128 Completed - Healthy Subjects Clinical Trials

High Flavonols Cocoa Intake for the Improvement of Body Fat Composition in Athletes

COCOFAT
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The decrease in body fat percentage improves exercise performance, reducing race time. The intake of cocoa improves the body fat composition in obese and diabetic people by improving their cardiovascular disease risk factors. Although epidemiological studies indicate that healthy subjects who consume cocoa have lower body fat composition, there is no study indicating whether cocoa improves fat composition in athletes. The aim of the study was to determine if the intake of cocoa rich in flavonoids improves the fat composition of athletes, modifying the systemic levels of adipokines (folistatin, myostatin and leptin), resulting in an improvement of physical performance.